Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenABCWY+OMV Antibody Persistence and Booster Response Study
NCT02451514Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2015
- Primary completion
- Nov 2015
- Modality
- Lipid-based Nanoparticles, Recombinant Proteins and Enzymes, Split/Subunit Vaccines
- Countries
- 3
01
Overview
Phase 2, open-label trial of MenABCWY+OMV vaccine in meningococcal disease (3 arms), sponsored by GSK. Primary endpoints: Percentages of Subjects With hSBA >= Lower Limit Quantitation (LLQ) at Day 31, Percentages of Subjects With hSBA >= 8 Against N. Meningitidis Serogroups A, C, W and Y at Day 31 and 3 more. Started Jun 2015; status: completed.
02
Drugs
MenABCWY+OMV vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT02451514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451514.